Physician profile
Alan D Dauer
NPI 1164493508
$7,160.80
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,495 · 2020: $1,243 · 2021: $1,764 · 2022: $1,218 · 2023: $816 · 2024: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,235.49 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $1,155.24 | 2019-2023 | Repatha, Otezla |
| Daiichi Sankyo INC. | $729.60 | 2019-2024 | Injectafer |
| Glaxosmithkline, LLC. | $605.98 | 2019-2024 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $447.72 | 2019-2024 | Jynarque |
| Calliditas Therapeutics US INC. | $393.29 | 2022-2024 | Tarpeyo |
| Horizon Therapeutics Plc | $311.21 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $230.30 | 2019-2024 | Mounjaro |
| Akebia Therapeutics INC | $190.55 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $183.22 | 2020-2023 | Terlivaz, Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.44 | 2020-2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $133.78 | 2019-2023 | Rayaldee |
| Vifor Pharma, INC. | $133.36 | 2019-2021 | |
| Abbvie INC. | $121.93 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $111.94 | 2022-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Dauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.